Medicare's prescription drug program :: competition issues and cost trends /
The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (generally referred to as the Medicare Modernization Act, or MMA) substantially expanded the federal Medicare program by creating the prescription drug benefit known as Part D. In fiscal year 2013, Medicare Part D covered 39...
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
New York :
Nova Publishers,
[2014]
|
| Schriftenreihe: | Health care in transition series.
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (generally referred to as the Medicare Modernization Act, or MMA) substantially expanded the federal Medicare program by creating the prescription drug benefit known as Part D. In fiscal year 2013, Medicare Part D covered 39 million people. The federal government spent 59 billion net of premiums on Part D in that year; after accounting for certain payments from states under the program, the net federal cost was 50 billion, which represented 10 percent of net federal spending for Medicare. This book discusses the cost tr. |
| Beschreibung: | Includes index. |
| Beschreibung: | 1 online resource |
| ISBN: | 9781634631532 1634631536 |
Internformat
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-ocn894666750 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d | ||
| 007 | cr ||||||||||| | ||
| 008 | 150210s2014 nyua ob 001 0 eng | ||
| 010 | |a 2020676824 | ||
| 040 | |a DLC |b eng |e rda |e pn |c DLC |d N$T |d E7B |d YDXCP |d OCLCF |d EBLCP |d DEBSZ |d AGLDB |d VTS |d STF |d M8D |d OCLCO |d OCLCQ |d OCLCO |d OCLCL | ||
| 019 | |a 914433370 |a 923677002 |a 928196491 | ||
| 020 | |a 9781634631532 |q (ebook) | ||
| 020 | |a 1634631536 | ||
| 020 | |z 1634631226 |q (hbk.) | ||
| 020 | |z 9781634631228 |q (hbk.) | ||
| 035 | |a (OCoLC)894666750 |z (OCoLC)914433370 |z (OCoLC)923677002 |z (OCoLC)928196491 | ||
| 043 | |a n-us--- | ||
| 050 | 4 | |a RA412.3 | |
| 072 | 7 | |a BUS |x 033070 |2 bisacsh | |
| 082 | 7 | |a 368.42600973 |2 23 | |
| 049 | |a MAIN | ||
| 245 | 0 | 0 | |a Medicare's prescription drug program : |b competition issues and cost trends / |c Gloria R. Pattinson, editor. |
| 264 | 1 | |a New York : |b Nova Publishers, |c [2014] | |
| 300 | |a 1 online resource | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Health care in transition | |
| 500 | |a Includes index. | ||
| 588 | 0 | |a Print version record. | |
| 505 | 0 | |a MEDICARE'S PRESCRIPTION DRUG PROGRAM: COMPETITION ISSUES AND COST TRENDS; MEDICARE'S PRESCRIPTION DRUG PROGRAM: COMPETITION ISSUES AND COST TRENDS; Library of Congress Cataloging-in-Publication Data; CONTENTS; PREFACE; Chapter 1: COMPETITION AND THE COST OF MEDICARE'S PRESCRIPTION DRUG PROGRAM; SUMMARY; SECTION 1. THE FEDERAL BUDGETARY COST OF MEDICARE PART D; SECTION 2. THE COMPETITIVE DESIGN OF MEDICARE PART D; SECTION 3. COMPARING MEDICARE PART D AND MEDICAID FEE FOR SERVICE. | |
| 505 | 8 | |a APPENDIX A. CALCULATING THE FEDERAL GOVERNMENT'S PAYMENTS AND BENEFICIARIES' COST-SHARING AMOUNTS FOR MEDICARE PART DAPPENDIX B. COMPARING THE USE AND PRICES OF DRUGS IN MEDICARE PART D AND MEDICAID FEE FOR SERVICE; Chapter 2: EFFECTS OF USING GENERIC DRUGS ON MEDICARE'S PRESCRIPTION DRUG SPENDING; SUMMARY; BOX 1. GENERIC DRUGS IN THE U.S. PHARMACEUTICAL MARKETPLACE; BOX 2. HOW COMPETITION FROM GENERIC DRUGS AFFECTS PRICES AND QUANTITIES OF PRESCRIPTION DRUGS; APPENDIX: DESCRIPTION OF DATA USED IN THIS ANALYSIS; Chapter 3: SPENDING PATTERNS FOR PRESCRIPTION DRUGS UNDER MEDICARE PART D. | |
| 505 | 8 | |a The medicare part d programnon-lis beneficiaries; part d insurance plans and the standard benefit; distribution of spending among non-lis beneficiaries; drivers of higher spending among non-lis beneficiaries; the federal contribution to part d spending for non-lis beneficiaries; implications of recent health care legislation for non-lis beneficiaries; lis beneficiaries; the federal contribution to spending for lis beneficiaries; comparing non-lis and lis beneficiaries; index. | |
| 520 | |a The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (generally referred to as the Medicare Modernization Act, or MMA) substantially expanded the federal Medicare program by creating the prescription drug benefit known as Part D. In fiscal year 2013, Medicare Part D covered 39 million people. The federal government spent 59 billion net of premiums on Part D in that year; after accounting for certain payments from states under the program, the net federal cost was 50 billion, which represented 10 percent of net federal spending for Medicare. This book discusses the cost tr. | ||
| 650 | 0 | |a Medicare. |0 http://id.loc.gov/authorities/subjects/sh85083053 | |
| 650 | 0 | |a Pharmaceutical services insurance |z United States. | |
| 650 | 0 | |a Medical care, Cost of |z United States. | |
| 650 | 2 | |a Medicare |0 https://id.nlm.nih.gov/mesh/D006278 | |
| 650 | 6 | |a Medicare. | |
| 650 | 6 | |a Assurance-médicaments |z États-Unis. | |
| 650 | 6 | |a Soins médicaux |x Coût |z États-Unis. | |
| 650 | 7 | |a BUSINESS & ECONOMICS |x Insurance |x Risk Assessment & Management. |2 bisacsh | |
| 650 | 7 | |a Medical care, Cost of |2 fast | |
| 650 | 7 | |a Medicare |2 fast | |
| 650 | 7 | |a Pharmaceutical services insurance |2 fast | |
| 651 | 7 | |a United States |2 fast |1 https://id.oclc.org/worldcat/entity/E39PBJtxgQXMWqmjMjjwXRHgrq | |
| 700 | 1 | |a Pattinson, Gloria R., |e editor. | |
| 758 | |i has work: |a Medicare's Prescription Drug Program (Text) |1 https://id.oclc.org/worldcat/entity/E39PD3XjwFhcvBgX9pBrxkgWQq |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Print version: |t Medicare's prescription drug program. |d New York : Nova Publishers, [2014] |z 9781634631228 |w (DLC) 2014498680 |
| 830 | 0 | |a Health care in transition series. |0 http://id.loc.gov/authorities/names/no2010153860 | |
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=886263 |3 Volltext |
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL2097190 | ||
| 938 | |a ebrary |b EBRY |n ebr10964975 | ||
| 938 | |a EBSCOhost |b EBSC |n 886263 | ||
| 938 | |a YBP Library Services |b YANK |n 12073446 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-ocn894666750 |
|---|---|
| _version_ | 1816882293192523776 |
| adam_text | |
| any_adam_object | |
| author2 | Pattinson, Gloria R. |
| author2_role | edt |
| author2_variant | g r p gr grp |
| author_facet | Pattinson, Gloria R. |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RA412 |
| callnumber-raw | RA412.3 |
| callnumber-search | RA412.3 |
| callnumber-sort | RA 3412.3 |
| callnumber-subject | RA - Public Medicine |
| collection | ZDB-4-EBA |
| contents | MEDICARE'S PRESCRIPTION DRUG PROGRAM: COMPETITION ISSUES AND COST TRENDS; MEDICARE'S PRESCRIPTION DRUG PROGRAM: COMPETITION ISSUES AND COST TRENDS; Library of Congress Cataloging-in-Publication Data; CONTENTS; PREFACE; Chapter 1: COMPETITION AND THE COST OF MEDICARE'S PRESCRIPTION DRUG PROGRAM; SUMMARY; SECTION 1. THE FEDERAL BUDGETARY COST OF MEDICARE PART D; SECTION 2. THE COMPETITIVE DESIGN OF MEDICARE PART D; SECTION 3. COMPARING MEDICARE PART D AND MEDICAID FEE FOR SERVICE. APPENDIX A. CALCULATING THE FEDERAL GOVERNMENT'S PAYMENTS AND BENEFICIARIES' COST-SHARING AMOUNTS FOR MEDICARE PART DAPPENDIX B. COMPARING THE USE AND PRICES OF DRUGS IN MEDICARE PART D AND MEDICAID FEE FOR SERVICE; Chapter 2: EFFECTS OF USING GENERIC DRUGS ON MEDICARE'S PRESCRIPTION DRUG SPENDING; SUMMARY; BOX 1. GENERIC DRUGS IN THE U.S. PHARMACEUTICAL MARKETPLACE; BOX 2. HOW COMPETITION FROM GENERIC DRUGS AFFECTS PRICES AND QUANTITIES OF PRESCRIPTION DRUGS; APPENDIX: DESCRIPTION OF DATA USED IN THIS ANALYSIS; Chapter 3: SPENDING PATTERNS FOR PRESCRIPTION DRUGS UNDER MEDICARE PART D. The medicare part d programnon-lis beneficiaries; part d insurance plans and the standard benefit; distribution of spending among non-lis beneficiaries; drivers of higher spending among non-lis beneficiaries; the federal contribution to part d spending for non-lis beneficiaries; implications of recent health care legislation for non-lis beneficiaries; lis beneficiaries; the federal contribution to spending for lis beneficiaries; comparing non-lis and lis beneficiaries; index. |
| ctrlnum | (OCoLC)894666750 |
| dewey-full | 368.42600973 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 368 - Insurance |
| dewey-raw | 368.42600973 |
| dewey-search | 368.42600973 |
| dewey-sort | 3368.42600973 |
| dewey-tens | 360 - Social problems and services; associations |
| discipline | Wirtschaftswissenschaften |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04948cam a2200673 i 4500</leader><controlfield tag="001">ZDB-4-EBA-ocn894666750</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">150210s2014 nyua ob 001 0 eng </controlfield><datafield tag="010" ind1=" " ind2=" "><subfield code="a"> 2020676824</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DLC</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="e">pn</subfield><subfield code="c">DLC</subfield><subfield code="d">N$T</subfield><subfield code="d">E7B</subfield><subfield code="d">YDXCP</subfield><subfield code="d">OCLCF</subfield><subfield code="d">EBLCP</subfield><subfield code="d">DEBSZ</subfield><subfield code="d">AGLDB</subfield><subfield code="d">VTS</subfield><subfield code="d">STF</subfield><subfield code="d">M8D</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCL</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">914433370</subfield><subfield code="a">923677002</subfield><subfield code="a">928196491</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781634631532</subfield><subfield code="q">(ebook)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1634631536</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">1634631226</subfield><subfield code="q">(hbk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9781634631228</subfield><subfield code="q">(hbk.)</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)894666750</subfield><subfield code="z">(OCoLC)914433370</subfield><subfield code="z">(OCoLC)923677002</subfield><subfield code="z">(OCoLC)928196491</subfield></datafield><datafield tag="043" ind1=" " ind2=" "><subfield code="a">n-us---</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RA412.3</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">BUS</subfield><subfield code="x">033070</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">368.42600973</subfield><subfield code="2">23</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Medicare's prescription drug program :</subfield><subfield code="b">competition issues and cost trends /</subfield><subfield code="c">Gloria R. Pattinson, editor.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York :</subfield><subfield code="b">Nova Publishers,</subfield><subfield code="c">[2014]</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Health care in transition</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes index.</subfield></datafield><datafield tag="588" ind1="0" ind2=" "><subfield code="a">Print version record.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">MEDICARE'S PRESCRIPTION DRUG PROGRAM: COMPETITION ISSUES AND COST TRENDS; MEDICARE'S PRESCRIPTION DRUG PROGRAM: COMPETITION ISSUES AND COST TRENDS; Library of Congress Cataloging-in-Publication Data; CONTENTS; PREFACE; Chapter 1: COMPETITION AND THE COST OF MEDICARE'S PRESCRIPTION DRUG PROGRAM; SUMMARY; SECTION 1. THE FEDERAL BUDGETARY COST OF MEDICARE PART D; SECTION 2. THE COMPETITIVE DESIGN OF MEDICARE PART D; SECTION 3. COMPARING MEDICARE PART D AND MEDICAID FEE FOR SERVICE.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">APPENDIX A. CALCULATING THE FEDERAL GOVERNMENT'S PAYMENTS AND BENEFICIARIES' COST-SHARING AMOUNTS FOR MEDICARE PART DAPPENDIX B. COMPARING THE USE AND PRICES OF DRUGS IN MEDICARE PART D AND MEDICAID FEE FOR SERVICE; Chapter 2: EFFECTS OF USING GENERIC DRUGS ON MEDICARE'S PRESCRIPTION DRUG SPENDING; SUMMARY; BOX 1. GENERIC DRUGS IN THE U.S. PHARMACEUTICAL MARKETPLACE; BOX 2. HOW COMPETITION FROM GENERIC DRUGS AFFECTS PRICES AND QUANTITIES OF PRESCRIPTION DRUGS; APPENDIX: DESCRIPTION OF DATA USED IN THIS ANALYSIS; Chapter 3: SPENDING PATTERNS FOR PRESCRIPTION DRUGS UNDER MEDICARE PART D.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">The medicare part d programnon-lis beneficiaries; part d insurance plans and the standard benefit; distribution of spending among non-lis beneficiaries; drivers of higher spending among non-lis beneficiaries; the federal contribution to part d spending for non-lis beneficiaries; implications of recent health care legislation for non-lis beneficiaries; lis beneficiaries; the federal contribution to spending for lis beneficiaries; comparing non-lis and lis beneficiaries; index.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (generally referred to as the Medicare Modernization Act, or MMA) substantially expanded the federal Medicare program by creating the prescription drug benefit known as Part D. In fiscal year 2013, Medicare Part D covered 39 million people. The federal government spent 59 billion net of premiums on Part D in that year; after accounting for certain payments from states under the program, the net federal cost was 50 billion, which represented 10 percent of net federal spending for Medicare. This book discusses the cost tr.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Medicare.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85083053</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Pharmaceutical services insurance</subfield><subfield code="z">United States.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Medical care, Cost of</subfield><subfield code="z">United States.</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Medicare</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D006278</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Medicare.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Assurance-médicaments</subfield><subfield code="z">États-Unis.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Soins médicaux</subfield><subfield code="x">Coût</subfield><subfield code="z">États-Unis.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BUSINESS & ECONOMICS</subfield><subfield code="x">Insurance</subfield><subfield code="x">Risk Assessment & Management.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medical care, Cost of</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicare</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmaceutical services insurance</subfield><subfield code="2">fast</subfield></datafield><datafield tag="651" ind1=" " ind2="7"><subfield code="a">United States</subfield><subfield code="2">fast</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PBJtxgQXMWqmjMjjwXRHgrq</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pattinson, Gloria R.,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="758" ind1=" " ind2=" "><subfield code="i">has work:</subfield><subfield code="a">Medicare's Prescription Drug Program (Text)</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PD3XjwFhcvBgX9pBrxkgWQq</subfield><subfield code="4">https://id.oclc.org/worldcat/ontology/hasWork</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="t">Medicare's prescription drug program.</subfield><subfield code="d">New York : Nova Publishers, [2014]</subfield><subfield code="z">9781634631228</subfield><subfield code="w">(DLC) 2014498680</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Health care in transition series.</subfield><subfield code="0">http://id.loc.gov/authorities/names/no2010153860</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=886263</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest Ebook Central</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL2097190</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ebrary</subfield><subfield code="b">EBRY</subfield><subfield code="n">ebr10964975</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">886263</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">12073446</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| geographic | United States fast https://id.oclc.org/worldcat/entity/E39PBJtxgQXMWqmjMjjwXRHgrq |
| geographic_facet | United States |
| id | ZDB-4-EBA-ocn894666750 |
| illustrated | Illustrated |
| indexdate | 2024-11-27T13:26:18Z |
| institution | BVB |
| isbn | 9781634631532 1634631536 |
| language | English |
| lccn | 2020676824 |
| oclc_num | 894666750 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource |
| psigel | ZDB-4-EBA |
| publishDate | 2014 |
| publishDateSearch | 2014 |
| publishDateSort | 2014 |
| publisher | Nova Publishers, |
| record_format | marc |
| series | Health care in transition series. |
| series2 | Health care in transition |
| spelling | Medicare's prescription drug program : competition issues and cost trends / Gloria R. Pattinson, editor. New York : Nova Publishers, [2014] 1 online resource text txt rdacontent computer c rdamedia online resource cr rdacarrier Health care in transition Includes index. Print version record. MEDICARE'S PRESCRIPTION DRUG PROGRAM: COMPETITION ISSUES AND COST TRENDS; MEDICARE'S PRESCRIPTION DRUG PROGRAM: COMPETITION ISSUES AND COST TRENDS; Library of Congress Cataloging-in-Publication Data; CONTENTS; PREFACE; Chapter 1: COMPETITION AND THE COST OF MEDICARE'S PRESCRIPTION DRUG PROGRAM; SUMMARY; SECTION 1. THE FEDERAL BUDGETARY COST OF MEDICARE PART D; SECTION 2. THE COMPETITIVE DESIGN OF MEDICARE PART D; SECTION 3. COMPARING MEDICARE PART D AND MEDICAID FEE FOR SERVICE. APPENDIX A. CALCULATING THE FEDERAL GOVERNMENT'S PAYMENTS AND BENEFICIARIES' COST-SHARING AMOUNTS FOR MEDICARE PART DAPPENDIX B. COMPARING THE USE AND PRICES OF DRUGS IN MEDICARE PART D AND MEDICAID FEE FOR SERVICE; Chapter 2: EFFECTS OF USING GENERIC DRUGS ON MEDICARE'S PRESCRIPTION DRUG SPENDING; SUMMARY; BOX 1. GENERIC DRUGS IN THE U.S. PHARMACEUTICAL MARKETPLACE; BOX 2. HOW COMPETITION FROM GENERIC DRUGS AFFECTS PRICES AND QUANTITIES OF PRESCRIPTION DRUGS; APPENDIX: DESCRIPTION OF DATA USED IN THIS ANALYSIS; Chapter 3: SPENDING PATTERNS FOR PRESCRIPTION DRUGS UNDER MEDICARE PART D. The medicare part d programnon-lis beneficiaries; part d insurance plans and the standard benefit; distribution of spending among non-lis beneficiaries; drivers of higher spending among non-lis beneficiaries; the federal contribution to part d spending for non-lis beneficiaries; implications of recent health care legislation for non-lis beneficiaries; lis beneficiaries; the federal contribution to spending for lis beneficiaries; comparing non-lis and lis beneficiaries; index. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (generally referred to as the Medicare Modernization Act, or MMA) substantially expanded the federal Medicare program by creating the prescription drug benefit known as Part D. In fiscal year 2013, Medicare Part D covered 39 million people. The federal government spent 59 billion net of premiums on Part D in that year; after accounting for certain payments from states under the program, the net federal cost was 50 billion, which represented 10 percent of net federal spending for Medicare. This book discusses the cost tr. Medicare. http://id.loc.gov/authorities/subjects/sh85083053 Pharmaceutical services insurance United States. Medical care, Cost of United States. Medicare https://id.nlm.nih.gov/mesh/D006278 Medicare. Assurance-médicaments États-Unis. Soins médicaux Coût États-Unis. BUSINESS & ECONOMICS Insurance Risk Assessment & Management. bisacsh Medical care, Cost of fast Medicare fast Pharmaceutical services insurance fast United States fast https://id.oclc.org/worldcat/entity/E39PBJtxgQXMWqmjMjjwXRHgrq Pattinson, Gloria R., editor. has work: Medicare's Prescription Drug Program (Text) https://id.oclc.org/worldcat/entity/E39PD3XjwFhcvBgX9pBrxkgWQq https://id.oclc.org/worldcat/ontology/hasWork Print version: Medicare's prescription drug program. New York : Nova Publishers, [2014] 9781634631228 (DLC) 2014498680 Health care in transition series. http://id.loc.gov/authorities/names/no2010153860 FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=886263 Volltext |
| spellingShingle | Medicare's prescription drug program : competition issues and cost trends / Health care in transition series. MEDICARE'S PRESCRIPTION DRUG PROGRAM: COMPETITION ISSUES AND COST TRENDS; MEDICARE'S PRESCRIPTION DRUG PROGRAM: COMPETITION ISSUES AND COST TRENDS; Library of Congress Cataloging-in-Publication Data; CONTENTS; PREFACE; Chapter 1: COMPETITION AND THE COST OF MEDICARE'S PRESCRIPTION DRUG PROGRAM; SUMMARY; SECTION 1. THE FEDERAL BUDGETARY COST OF MEDICARE PART D; SECTION 2. THE COMPETITIVE DESIGN OF MEDICARE PART D; SECTION 3. COMPARING MEDICARE PART D AND MEDICAID FEE FOR SERVICE. APPENDIX A. CALCULATING THE FEDERAL GOVERNMENT'S PAYMENTS AND BENEFICIARIES' COST-SHARING AMOUNTS FOR MEDICARE PART DAPPENDIX B. COMPARING THE USE AND PRICES OF DRUGS IN MEDICARE PART D AND MEDICAID FEE FOR SERVICE; Chapter 2: EFFECTS OF USING GENERIC DRUGS ON MEDICARE'S PRESCRIPTION DRUG SPENDING; SUMMARY; BOX 1. GENERIC DRUGS IN THE U.S. PHARMACEUTICAL MARKETPLACE; BOX 2. HOW COMPETITION FROM GENERIC DRUGS AFFECTS PRICES AND QUANTITIES OF PRESCRIPTION DRUGS; APPENDIX: DESCRIPTION OF DATA USED IN THIS ANALYSIS; Chapter 3: SPENDING PATTERNS FOR PRESCRIPTION DRUGS UNDER MEDICARE PART D. The medicare part d programnon-lis beneficiaries; part d insurance plans and the standard benefit; distribution of spending among non-lis beneficiaries; drivers of higher spending among non-lis beneficiaries; the federal contribution to part d spending for non-lis beneficiaries; implications of recent health care legislation for non-lis beneficiaries; lis beneficiaries; the federal contribution to spending for lis beneficiaries; comparing non-lis and lis beneficiaries; index. Medicare. http://id.loc.gov/authorities/subjects/sh85083053 Pharmaceutical services insurance United States. Medical care, Cost of United States. Medicare https://id.nlm.nih.gov/mesh/D006278 Medicare. Assurance-médicaments États-Unis. Soins médicaux Coût États-Unis. BUSINESS & ECONOMICS Insurance Risk Assessment & Management. bisacsh Medical care, Cost of fast Medicare fast Pharmaceutical services insurance fast |
| subject_GND | http://id.loc.gov/authorities/subjects/sh85083053 https://id.nlm.nih.gov/mesh/D006278 |
| title | Medicare's prescription drug program : competition issues and cost trends / |
| title_auth | Medicare's prescription drug program : competition issues and cost trends / |
| title_exact_search | Medicare's prescription drug program : competition issues and cost trends / |
| title_full | Medicare's prescription drug program : competition issues and cost trends / Gloria R. Pattinson, editor. |
| title_fullStr | Medicare's prescription drug program : competition issues and cost trends / Gloria R. Pattinson, editor. |
| title_full_unstemmed | Medicare's prescription drug program : competition issues and cost trends / Gloria R. Pattinson, editor. |
| title_short | Medicare's prescription drug program : |
| title_sort | medicare s prescription drug program competition issues and cost trends |
| title_sub | competition issues and cost trends / |
| topic | Medicare. http://id.loc.gov/authorities/subjects/sh85083053 Pharmaceutical services insurance United States. Medical care, Cost of United States. Medicare https://id.nlm.nih.gov/mesh/D006278 Medicare. Assurance-médicaments États-Unis. Soins médicaux Coût États-Unis. BUSINESS & ECONOMICS Insurance Risk Assessment & Management. bisacsh Medical care, Cost of fast Medicare fast Pharmaceutical services insurance fast |
| topic_facet | Medicare. Pharmaceutical services insurance United States. Medical care, Cost of United States. Medicare Assurance-médicaments États-Unis. Soins médicaux Coût États-Unis. BUSINESS & ECONOMICS Insurance Risk Assessment & Management. Medical care, Cost of Pharmaceutical services insurance United States |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=886263 |
| work_keys_str_mv | AT pattinsongloriar medicaresprescriptiondrugprogramcompetitionissuesandcosttrends |